Alfonso Quintás-Cardama, MD, joined Foghorn Therapeutics in 2023 as Chief Medical Officer. He brings extensive experience and expertise in oncology and as a leukemia expert.

Alfonso joined Foghorn from TCR2 where he was the CMO and led the development of the company’s cell therapy platform. Prior to this he served as the global clinical leader at Novartis from 2014 to 2016, where he led the development of tisagenlecleucel (Kymriah™, CTL019), the first FDA-approved CAR-T cell therapy. His prior experience includes a role as the head of clinical development for cell therapies at GSK where he was instrumental in building GSK’s cell therapies unit, and from 2009 to 2014, he was a faculty member of the Department of Leukemia at MD Anderson Cancer Center, where he developed multiple FDA-approved targeted agents for the treatment of myeloid malignancies.